Flexible Solutions International, Inc. reports developments in specialty chemicals, biodegradable polymers, and water and energy conservation technologies. The company’s NanoChem Solutions Inc. subsidiary produces water-soluble products based on thermal polyaspartate biopolymers for uses including oil extraction, detergent ingredients, water treatment, scale inhibition, and crop enhancement.
FSI news commonly covers revenue releases, annual and quarterly financial results, conference-call updates, production activity, and facility changes tied to its Illinois food-grade operations and Panama agriculture and industrial products factory. Company updates also address crop nutrient availability chemistry, food and nutrition supplement manufacturing, and water-conservation products for drinking water, agriculture, industrial markets, and swimming pools.
Flexible Solutions International (NYSE-AMERICAN: FSI) announced a significant capital expenditure to acquire a production line for vial filling of injectable drugs such as GLP1 for weight loss. The $2.5 million investment secures a nearly-unused production line capable of producing 22.5 million vials per year, reducing the typical wait time and cost for such equipment. The company aims to leverage its existing clean room skills from its food/nutrition division to enter the high-risk, high-reward drug compounding market. CEO Dan O’Brien emphasized the need for de-risking this venture by securing sales and potentially partnering with experienced players in the industry. The company plans to proceed only if the benefits to shareholders outweigh the risks, with a minimum one-year timeframe before production can commence, subject to regulatory approvals.
Flexible Solutions International (FSI) has released its financial results for Q1 2024. The company reported sales of $9.22 million, a decrease of 6% from the $9.85 million in Q1 2023.
Net income fell to $457,226 ($0.04 per share) from $884,369 ($0.07 per share) in the previous year, due to higher costs and one-time expenses related to the closure of its Naperville R&D facility.
Operating cash flow for Q1 2024 was $1.34 million ($0.11 per share), down from $1.73 million ($0.14 per share) in Q1 2023. CEO Daniel B. O’Brien highlighted the progress in operational streamlining and new opportunities in the food and nutraceutical markets expected to drive revenue in 2024.
A conference call is scheduled for May 16, 2024, at 11:00 AM Eastern Time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.